| Nov 15 |
Despite Journey Medical's Pullback, Insiders Still Gained US$118k
|
| Nov 13 |
Journey Medical GAAP EPS of -$0.12 beats by $0.03, revenue of $14.63M beats by $0.24M
|
| Nov 12 |
Journey Medical Corporation (DERM) Reports Q3 Loss, Tops Revenue Estimates
|
| Nov 12 |
Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
|
| Nov 5 |
FDA approves Journey Medical’s rosacea treatment Emrosi
|
| Nov 4 |
Journey gets FDA okay for Emrosi, releases preliminary Q3 earnings report
|
| Nov 4 |
Journey Medical (DERM) Soars 7.3%: Is Further Upside Left in the Stock?
|
| Nov 4 |
Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea
|
| Oct 25 |
Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference
|
| Oct 17 |
SWK Holdings Provides Portfolio Update
|
